7 › 7.3
7.3 Clinical presentation
Pages 42–44 · open in PDF
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 42 · PDF
42 with AF, the percentage of effective biventricular pacing (without fusion or pseudofusion) is an important focus. Further details on CRT follow-up and optimization are outlined in an HFA position paper.435
6.2.5. Other cardiac implantable electronic devices
6.2.6. Other implantable devices It has been hypothesized that an interatrial shunt could improve HF symptoms and outcomes by decompressing the left atrium. In the RELIEVE-HF study, 508 patients with HF and predominantly NYHA class III symptoms and any LVEF were randomized to transcatheter shunt implantation vs a sham procedure.442 After 2 years, no difference emerged in the primary effectiveness outcome [hierarchical composite ranking of all-cause death, cardiac transplantation or LV assist device (LVAD) implantation, HFH, outpatient WHF events, and change in QoL]. Importantly, patients with reduced LVEF had fewer adverse CV events with shunt treatment, whereas patients with HFpEF had more CV events. In the REDUCE LAP-HF II study in patients with LVEF ≥40%, the atrial shunt device was no better than the sham procedure in terms of the hierarchical composite of CV death or nonfatal ischaemic stroke at 12 months, rate of total HF events up to 24 months, and change in QoL at 12 months.443
7. Decompensated heart failure 7.1. Definition and epidemiology Decompensated HF is defined as acute or gradual onset of symptoms and/or signs of HF, severe enough to require urgent medical attention and treatment initiation or intensification. DHF can lead to an unplanned hospital admission, an emergency department visit, or an unplanned ambulatory visit requiring treatment for HF. DHF may present as either worsening of preexisting HF or as the initial manifestation of the disease (de novo HF). In the setting of patients with pre-existing HF, WHF is characterized by a deterioration in the symptoms and/or signs of HF and represents an event in HF progression, whereas DHF is specifically characterized by the requirement for treatment modification.444 Decompensated HF is associated with a high risk of death: 3%–10% during HF admission; 20%–30% at 1 year, >50% after 5 years.445–450 Compared to DHF occurring in patients with preexisting HF, de novo DHF may be associated with higher inhospital death, but lower post-discharge death and rehospitalization rates.451–453 Following a hospitalization for DHF, 1-year rehospitalization rates range between 35% and 44%.447,448,453–455 In addition, up to 50% of patients with HF
require intensification of treatment in the emergency service or in outpatient settings.456–462
7.2. Diagnosis Decompensated HF requires prompt diagnosis to ensure early treatment.463 If DHF is suspected, assessment of signs and symptoms of congestion and hypoperfusion must be done at the first medical contact. Non-invasive blood pressure, respiratory rate, pulse oximetry monitoring, body temperature measurement, and ECG should be performed early.464 In haemodynamically unstable patients with suspected hypoperfusion, assessment of serum lactate levels should be performed promptly.465 The currently recommended, non-age-adjusted, natriuretic peptide ‘rule-out’ thresholds for DHF are: NT-proBNP <300 pg/mL, or BNP <100 ng/mL, or MR-proANP <120 pg/mL.157,466–469 However, if clinical suspicion of HF remains despite values below ‘rule-out’ thresholds, specialist assessment and echocardiogram should be sought. Age-related thresholds for NT-proBNP, above which DHF is considered ‘likely’, are given in the footnote of Figure 11. In the older population, using the age-related NT-proBNP threshold may aid appropriate triage and help reduce unnecessary exams. NT-pro-BNP >5000 pg/mL indicates very high risk, and admission is generally recommended. For other laboratory tests and investigations for patients with suspected DHF, see Supplementary data online, Table S11. Initial investigations are carried out to diagnose DHF and rapidly detect any possible triggers. Transthoracic echocardiography should be performed in patients with high levels of NT-proBNP and in those for whom there is a high clinical suspicion of DHF. Where trained personnel are available, lung ultrasound identifies patients with pulmonary congestion and has utility in serial assessments.470–473
7.3. Clinical presentation Congestion and hypoperfusion are two major clinical manifestations of DHF.447,453 Congestion may stem from fluid overload, fluid redistribution, increased vascular permeability, and increased intracardiac pressures. Different clinical, laboratory, and imaging utilities should be used to assess congestion and its dynamic changes (see Supplementary data online, Table S12). Hypoperfusion is not a synonym for hypotension,474,475 although patients with DHF and hypotension also experience inadequate perfusion. An objective marker, serum lactate, may help identify patients with peripheral hypoperfusion and monitor therapy.465 Signs and symptoms associated with congestion and hypoperfusion are reported in Table 12. Four categories of DHF can be recognized based on clinical presentation: decompensated left-sided HF, decompensated right-sided HF, acute pulmonary oedema (APO), and cardiogenic shock (CS). Pathophysiology, timing of onset, and speed of deterioration differ between the four categories, but possible overlaps exist.
7.3.1. Decompensated left-sided heart failure Decompensated left-sided HF, in its classical clinical presentation, is characterized by a gradual onset of signs and symptoms with accumulating congestion as the primary pathophysiological process.476 It may occur in patients across the spectrum of LVEF and, in advanced stages, can lead to RV dysfunction and
In a small unblinded RCT, cardiac contractility modulation marginally improved peak oxygen uptake and QoL in patients with advanced HFrEF and a QRS <130 ms.438 In a small pilot study, cardiac contractility modulation improved the Kansas City Cardiomyopathy Questionnaire (KCCQ) score by 18 points in patients with HFpEF.439 No clinical outcome studies have emerged. Similarly, baroreceptor activation therapy led to improvements in 6-min walk distance and QoL in an unblinded RCT, but long-term clinical outcome data were neutral.440,441 Current evidence for these CIEDs is insufficient to support guideline recommendations. Although promising, these findings require confirmation in large, well-designed trials.439
Page 43 · PDF
shock; DHF, decompensated heart failure; ECG, electrocardiogram; LUS, lung ultrasound; MR-proANP, mid-regional pro-atrial natriuretic peptide; NT-proBNP, N-terminal pro-B-type natriuretic peptide. aSee Supplementary data online, Table S11 for more details on admission investigations in DHF. bIn case of APO or CS, early treatment is recommended. cThe currently recommended, non-age-adjusted, natriuretic peptide ‘rule-out’ thresholds for DHF are: NT-proBNP <300 pg/mL, or BNP <100 ng/mL, or MR-proANP <120 pg/mL. Combination with age-related ‘likely’ rule-in thresholds may reduce unnecessary exams: NT-proBNP >450 pg/mL (<50 years), NT-proBNP >900 pg/mL (50– 74 years), NT-proBNP >1800 pg/mL (>74 years). dIn case of DHF unlikely, look for other causes of symptoms.
decompensated right-sided heart failure. Thus, both pulmonary and peripheral congestion may be present. Hypoperfusion can occur.447,465,476 Treatment is mainly based on decongestion by means of diuretic therapy. Site of care can be outpatient clinic or hospital.
7.3.2. Decompensated right-sided heart failure Decompensated isolated right-sided HF is characterized by elevated RV and right atrial pressures, leading to systemic congestion and, in more advanced stages, hypoperfusion. It is often
associated with tricuspid regurgitation (TR) and can also impair LV filling and reduce systemic cardiac output through ventricular interdependence. Pulmonary embolism and acute MI involving the right ventricle are possible causes of decompensated right HF that need to be excluded during initial evaluation and treated. Fluid overload, elevated central venous pressures, and multiorgan dysfunction are the most frequent elements of the clinical picture of the disease. In the most severe cases, it can manifest as a refractory shock. The RV function and its effect on other organs (kidney, liver) usually determine the clinical
Figure 11 Diagnosing decompensated heart failure. APO, acute pulmonary oedema; BNP, B-type natriuretic peptide; CS, cardiogenic
Page 44 · PDF
Table 12 Signs, symptoms, and altered laboratory tests in congestion and hypoperfusion profiles
SCAI classification for cardiogenic shock
A patient who is not currently
experiencing signs or symptoms of CS but is at risk for development of CS.
Peripheral oedema Abdominal distension
STAGE B ‘Beginning/pre-shock’
A patient who has clinical evidence of hemodynamic instability (including
relative hypotension or tachycardia)
Dizziness Mental confusion
Pleural effusion Elevated serum
Elevated bilirubin, ALP, GGT
A patient that manifests with
‘Classic’ cardiogenic shock
hypoperfusion requiring intervention (inotrope, vasopressor, or mechanical support).
A patient that is similar to stage C but
deteriorating with failure to respond to A patient with refractory shock or cardiac arrest requiring multiple simultaneous acute interventions, including CPR.
CPR, cardiopulmonary resuscitation; CS, cardiogenic shock; MI, myocardial infarction; SCAI, Society for Cardiovascular Angiography and Interventions.
trajectory, thus a close monitoring of kidney and hepatic function is needed. Onset can be gradual or rapid depending on causes, triggers, and precipitating factors. Optimal care requires a multifaceted approach, including diuretics, judicious fluid management, appropriate use of inotropes and vasopressors, and mechanical circulatory support (MCS) when indicated.
7.3.3. Acute pulmonary oedema Acute pulmonary oedema is a life-threatening condition that needs prompt, optimally targeted rescue therapy.477,478 Clinical criteria for the diagnosis of APO include signs and symptoms of respiratory distress [dyspnoea with orthopnoea, respiratory failure (hypoxaemia with or without hypercapnia), tachypnoea (>25 breaths/min), and increased work of breathing], caused by massive pulmonary congestion, which typically develops over a short period of time.477 The major objectives of the treatment are relieving pulmonary congestion, treating respiratory insufficiency, and ensuring peripheral perfusion. The mechanism of development of congestion is complex, with a predominant fluid redistribution that implies pulmonary congestion without total volume overload, primarily due to blood shift into the pulmonary circulation. Such patients usually do not need high doses of diuretics, but they may need vasodilators. The cause of decompensation should be investigated in every patient, and causal treatment, if possible, is imperative.
7.3.4. Cardiogenic shock Cardiogenic shock is defined as a state of critical end-organ hypoperfusion caused by primary cardiac dysfunction.479–481 The Shock Academic Research Consortium (SHARC) consensus defines CS as a cardiac disorder that results in both clinical
and biochemical evidence of sustained tissue hypoperfusion.482 Generally, CS is characterized by hypoperfusion and hypotension; however, no specific blood pressure cut-off is defined, as CS is a complex clinical condition, involving many parameters and nuances. Thus, any arbitrary blood pressure threshold will have inherent limitations. CS may also present as hypoperfusion with normotension, which has better prognosis than hypotensive CS.483,484 Importantly, septic and hypovolaemic shock also manifests with hypotension and end-organ hypoperfusion, and mixed forms of shock often exist simultaneously.480,485 Clinical features of hypoperfusion are reported in Table 12. Biochemical manifestation of inadequate tissue perfusion is best measured by arterial lactate, where a value of >2 mmol/L is required.479,480 Additional markers used in assessment of hypoperfusion are acute kidney injury and/or acute hepatic injury.480 The Society for Cardiovascular Angiography and Interventions introduced a staging scheme—SCAI classification—to address the severity of CS.479 Based on this, there are five categories of CS: (A) at risk, (B) pre-shock, (C) classic, (D) deteriorating, and (E) extremis (Table 13).
7.4. General management In-hospital management of DHF can be divided into three general phases (Figure 12). Importantly, each clinical category of DHF has different trajectories through these phases. For instance, CS patients usually remain in phase 1 for several days and may never reach phase 2.474 On the other hand, patients with uncomplicated decompensated left-sided or right-sided HF or APO can experience quick transition through all phases of treatment.
initial interventions. STAGE E ‘Extremis’
ALP, alkaline phosphatase; GGT, gamma glutamyl transpeptidase.